Determination of the Toxicity of Standard Dose Cetuximab Together With Concurrent Individualised, Isotoxic Accelerated Radiotherapy and Cisplatin-vinorelbine for Patients With Stage III Non-small Cell Lung Cancer: A Phase I Study

NCT00522886 Phase 1 COMPLETED

To determine the MTD toxicity of standard dose cetuximab together with concurrent individualized, isotoxic accelerated radiotherapy and cisplatin-vinorelbine

Details

Lead sponsor	Maastricht Radiation Oncology
Phase	Phase 1
Status	COMPLETED
Enrolment	24
Start date	2007-04

Conditions

• Non-small Cell Lung Cancer

Interventions

• Cetuximab

Primary outcomes

• Maximum Tolerated Dose (MTD) 3 months after the ende of chemo-radiation — 3 months

Countries

Netherlands